论文部分内容阅读
苯噻唑力复霉素(R75-1)是一种新的半合成利福霉素,药理研究证明它具有对结核分枝杆菌的强大制菌作用而对动物无明显的毒性,初步用于临床治疗成人肺结核64例。治疗方案,“R75-1”450～600毫克,合并异菸肼300毫克,均于每天早晨一次顿服,疗程6个月。对照组:国产利福平(甲哌力复霉素)及异菸肼联合治疗,剂量及疗程相同。治疗结果:痰菌阴转率初治为92.86％,复治为51.72％,病变吸收显效率初治为95％,复治为26.56％;空洞闭合率或显效率初治为88.24％,复治为39.66％。治疗效果与对照组比较很近似(P>0.05)。“R75-1”的毒副作用小,仅1例出现一过性轻微肝损害。
Benzthiazurin (R75-1) is a new semi-synthetic rifamycin, pharmacological studies have shown that it has a strong antibacterial effect on Mycobacterium tuberculosis without significant toxicity to animals, initially for clinical Treatment of 64 cases of adult tuberculosis. Treatment options, “R75-1” 450 ~ 600 mg, combined with isoniazid 300 mg, are Dayton clothing every morning, a course of 6 months. Control group: domestic rifampicin (methylprednisolone) and isoniazid combination therapy, the same dose and course of treatment. Treatment results: sputum negative conversion rate of 92.86% for initial treatment, retreatment was 51.72%, effective rate of disease was 95% for initial treatment, retreatment was 26.56%; empty closed rate or markedly effective initial treatment was 88.24%, retreatment 39.66%. The treatment effect is similar to the control group (P> 0.05). The side effects of “R75-1” were small, with only 1 minor transient liver damage.